Effect of hormone replacement therapy on postmenopausal endometrial bleeding

Pathology and Oncology Research

Volumn 13, Issue 4, 2007, Pages 351-359

  Magyar, Zoltan ^a   Berkes, Eniko ^a   Csapo, Zsolt ^a   Papp, Zoltan ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Climacterium; Irregular bleeding; Menopause; Postmenopausal hormone therapy

Indexed keywords

CYPROTERONE ACETATE PLUS ESTRADIOL VALERATE; DYDROGESTERONE PLUS ESTRADIOL; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTRIMAX; ESTROFEM; ESTROGEN; GESTAGEN; PAUSOGEST; TIBOLONE; TRISEQUENS; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLIMACTERIUM; CONTROLLED STUDY; DRUG EFFECT; ENDOMETRIUM; ENDOMETRIUM ATROPHY; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HISTOLOGY; HORMONAL CARCINOGENESIS; HORMONAL REGULATION; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; HYSTEROGRAPHY; HYSTEROSCOPY; INCIDENCE; MAJOR CLINICAL STUDY; PATIENT CARE; POSTMENOPAUSE; TREATMENT INDICATION; TREATMENT OUTCOME; UTERUS BLEEDING;

EID: 39649109226     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02940316     Document Type: Article

References (51)

1. Anastasiadis PG, Koutlaki NG, Skaphida PG et al: Endometrial polypus: prevalence, detection, and malignant potential in women with abnormal uterine bleeding. Eur J Gynaecol Oncol 21: 180-183, 2000.
2. Astrup K, Olivarius N: Frequency of spontaneously occurring postmenopausal bleeding in the general population. Acta Obstet Gynecol Scand 83: 203-205, 2004.
3. Bachmann LM, Riet G, Clark TJ et al: Probability analysis for diagnosis of endometrial hyperplasia and cancer in post-menopausal bleeding: an approach for a rational diagnostic workup. Acta Obstet Gynecol Scand 82: 1-6, 2003.
4. Bernard JP, Rizk E, Camatte S et al: Saline contrast sonohysterography in the preoperative assessment of benign intrauterine disorders. Ultrasound Obstet Gynecol 17: 145-149, 2001.
5. Burger HG, Dudley EC, Hopper JL et al: The endocrinology of the menopausal transition: a cross-sectional study of a population-based sample. J Clin Endocrinol Metab 80: 3537-3545, 1995.
6. Cerin A, Heldaas K, Moeller B: Adverse endometrial effects of long-cycle estrogen and progestagen replacement therapy. The Scandinavian Long-Cycle Study Group. New Engl J Med 334: 668-669, 1996.
7. Clark TJ, Barton PM, Coomarasamy A et al: Investigating postmenopausal bleeding for endometrial cancer: cost-effectiveness of initial diagnostic strategies. Br J Obstet Gynecol 113: 502-510, 2006.
8. Dahmoun M, Ödmark IS, Risberg B et al: Apoptosis, proliferation, and sex steroid receptors in postmenopausal endometrium before and during HRT. Maturitas 49: 114-123, 2004.
9. Dijkhuizen FP, Mol BW, Brolmann HA et al: The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer 89: 1765-1772, 2000.
10. Epstein E, Valentin L: Managing women with post-menopausal bleeding. Best Pract Res Clin Obstet Gynaecol 18: 125-143, 2004.
11. Erkkola R, Kumento U, Lehmuskoski S et al: No increased risk of endometrial hyperplasia with fixed long-cycle oestrogen-progestogen therapy after five years. J Br Menopause Soc 10: 9-13, 2004.
12. Farquhar CM, Lethaby A, Sowter M et al: An evaluation of risk factors for endometrial hyperplasia in premenopausal women with abnormal menstrual bleeding. Am J Obstet Gynecol 181: 525-529, 1999.
13. Ferenczy A: Pathophysiology of endometrial bleeding. Maturitas 45: 1-14, 2003.
14. Ferenczy A, Gelfand MM: Endometrial histology and bleeding patterns in postmenopausal women taking sequential, combined E2 and dydrogesterone. Maturitas 26: 219-226, 1997.
15. Goldschmit R, Katz Z, Blickstein I et al: The accuracy of endometrial Pipelle sampling with and without sonographic measurement of endometrial thickness. Obstet Gynecol 82: 727-730, 1993.
16. Goldstein SR, Zeltser I, Horan CK et al: Ultrasonography-based triage for perimenopausal patients with abnormal uterine bleeding. Am J Obstet Gynecol 177: 102-108, 1997.
17. Grady D, Ernster VL: Hormone replacement therapy and endometrial cancer: are current regimens safe? J Natl Cancer Inst 89: 1088-1089, 1997.
18. Grimes DA: Diagnostic dilation and curettage: a reappraisal. Am J Obstet Gynecol 142: 1-6, 1982.
19. Gusberg SB: Precursors of corpus carcinoma. Estrogens and adenomatous hyperplasia. Am J Obstet Gynecol 54: 905-907, 1947.
20. Hickey M, Fraser IS: The structure of endometrial microvessels. Hum Reprod 3: 57-66, 2000.
21. Hickey M, Higham J, Sullivan M et al: Endometrial bleeding in hormone replacement therapy users: preliminary findings regarding the role of matrix metalloproteinase 9 (MMP-9) and tissue inhibitors of MMPs. Fertil Steril 75: 288-296, 2001.
22. Hickey M, Pillai G, Higham JM et al: Changes in endometrial blood vessels in the endometrium of women with hormone replacement therapy-related irregular bleeding. Hum Reprod 18: 1100-1106, 2003.
23. Holst T, Lang E, Winkler U et al: Bleeding patterns in peri and postmenopausal women taking a continuous combined regimen of estradiol with norethisterone acetate or a conventional sequential regimen of conjugated equine estrogens with medrogestone. Maturitas 43: 265-275, 2002.
24. Hulley S, Grady D, Bush T et al: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/Progestin Replacement Study (HERS). JAMA 280: 605-613, 1998.
25. Kimura T, Kamiura S, Yamamoto T et al: Abnormal uterine bleeding and prognosis of endometrial cancer. Int J Gynecol Obstet 85: 145-150, 2004.
26. Klein NA, Soules MR: Endocrine changes of the perimenopause. Clin Obstet Gynecol 41: 912-920, 1998.
27. March CM: Bleeding problems and treatment. Clin Obstet Gynecol 41: 928-939, 1998.
28. Mirkin S, Navarro F, Archer DF: Hormone therapy and endometrial angiogenesis. Climact 6: 273-277, 2003.
29. Mishell DR Jr, Kaunitz AM: Devices for endometrial sampling. A comparison. J Reprod Med 43: 180-184, 1998.
30. Mossa B, Imperato F, Marziani R et al: Hormonal replacement therapy and evaluation of intrauterine pathology in postmenopausal women: a ten-year study. Eur J Gynaecol Oncol 24: 507-512, 2003.
31. Oehler MK, MacKenzie I, Kehoe S et al: Assessment of abnormal bleeding in menopausal women: an update. J Br Menopause Soc 9: 117-121, 2003.
32. Omodei U, Ferrazzia E, Ruggeri C et al: Endometrial thickness and histological abnormalities in women on hormonal replacement therapy: a transvaginal ultrasound/hysteroscopic study. Ultrasound Obstet Gynecol 15: 317-320, 2000.
33. Papp Z (ed): A szülészet- nõgyógyászat tankönyve. Semmelweis Kiadó, Budapest, 2002.
34. Perrone G, DeAngelis C, Critelli C et al: Hysteroscopic findings in postmenopausal abnormal uterine bleeding: a comparison between HRT users and non-users. Maturitas 43: 251-255, 2002.
35. Pike MC, Peters RK, Cozen W: Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 89: 1110-1116, 1997.
36. Reslova T, Tosner J, Resl M et al: Endometrial polypus. A clinical study of 245 cases. Arch Gynecol Obstet 262: 133-139, 1999.
37. Samsioe G.: Hormone replacement therapy: aspects of bleeding problems and compliance. Int J Fertil Menopausal Stud 41: 11-15, 1996.
38. Schmidt T, Nawroth F, Breidenbach M et al: Differential indication for histological evaluation of endometrial fluid in postmenopause. Maturitas 50: 177-181, 2005.
39. Seltzer VL, Benjamin F, Deutsch S: Perimenopausal bleeding patterns and pathological findings. J Am Med Womens Assoc 45: 132-134, 1990.
40. Shapiro S, Kelly JP, Rosenberg L et al: Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Engl J Med 313: 969-972, 1985.
41. Sivridis E, Giatromanolaki A: Proliferative activity in postmenopausal endometrium: the lurking potential for giving rise to an endometrial adenocarcinoma. J Clin Pathol 57: 840-844, 2004.
42. Toon VG, Patrick N: Endometrial safety of hormone replacement therapy: review of literature. Maturitas 42: 93-104, 2002.
43. Valle RF: Office hysteroscopy. Clin Obstet Gynecol 42: 276-289, 1999.
44. Van de Weijer PHM, Scholten P, van der Mooren MJ: Bleeding patterns and endometrial histology in postmenopausal women taken low dose, sequential combined E2 and dydrogesterone. Climact 2: 1-9, 1999.
45. Weber AM, Belinson JL, Piedmonte MR: Risk factors for endometrial hyperplasia and cancer among women with abnormal bleeding. Obstet Gynecol 93: 594-598, 1999.
46. Wildemeersch D, Schacht E, Wildemeersch P: Performance and acceptability of intrauterine release of levonorgestrel with a miniature delivery system for hormonal substitution therapy, contraception and treatment in peri- and postmenopausal women. Maturitas 44: 237-245, 2003.
47. Woodruff JD, Pickar JH: Incidence of endometrial hyperplasia in postmenopausal women taken conjugated estrogens (Premarin) with medroxyprogesterone acetate versus conjugated estrogens alone. Am J Obstet Gynecol 170: 1213-1223, 1994.
48. Wren BG, Brown L: Compliance with hormonal replacement therapy. Maturitas 13: 17-21, 1991.
49. Writing Group for the PEPI Trial. Effects of hormonal replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen-Progestin Interventions (PEPI) Trial. JAMA 275: 370-3751996.
50. Zerbe MJ, Zhang J, Bristow RE et al: Retrograde seeding of malignant cells during hysteroscopy in presumed early endometrial cancer. Gynecol Oncol 79: 55-58, 2000.
51. Zupi E, Sbracia M, Marconi D et al: TNFalpha expression in hyperplastic endometrium. Am J Reprod Immunol 44: 153-159, 2000.